Avoro Capital Advisors LLC
Q1 2023 13F-HR Holdings
Net value change ($000)
+53,660
(0.8%)
New positions
2
Sold out positions
0
Turnover %
0.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| APLS | 183,470 | 33.4% |
| Seagen Inc. | 122,591 | 50.6% |
| SRPT | 91,663 | 22.3% |
| DICE Therapeutics, Inc. | 34,371 | 43.6% |
| KRYS | 28,405 | 25.4% |
| CymaBay Therapeutics, Inc. | 25,235 | 39.1% |
| IVERIC bio, Inc. | 20,926 | 14.5% |
| KYMR | 18,128 | 18.9% |
| VRCA | 17,225 | NEW |
| BMRN | 15,648 | 4.3% |
Top Reduces (Value $000, Stocks/ETFs)
| UTHR | -153,963 | -19.3% |
| MDGL | -78,048 | -16.2% |
| Mirati Therapeutics, Inc. | -45,166 | -17.9% |
| ALNY | -41,249 | -15.7% |
| Horizon Therapeutics Public Ltd Co | -32,620 | -4.1% |
| FOLD | -24,471 | -7.5% |
| ASND | -22,096 | -5.8% |
| XENE | -17,836 | -9.2% |
| BCRX | -16,991 | -16.4% |
| WHWK | -15,928 | -43.6% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
5,693
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|